[PDF] from leprahealthinaction.orgH SINGH, B NEL, V DEY, P TIWARI… - Leprosy …, 2011 - leprahealthinaction.org ... Lepr Rev (2011) 82, 17–24 0305-7518/11/064053+08 $1.00 q Lepra 17 Page 2. ... Exclusion criteria: Those, who had taken any other medication during this study, Patients with any other chronic illness Those who had interrupted the MDT medication Patient with lepra reaction ... Related articles - View as HTML - All 3 versions
[PDF] from leprahealthinaction.orgA MAGHANOY, I MALLARI, M BALAGON… - Leprosy …, 2011 - leprahealthinaction.org ... Lepr Rev (2011) 82, 65–69 0305-7518/11/064053+05 $1.00 q Lepra 65 ... Subjects were also encouraged to report to the clinic between scheduled visits for unusual skin problems, including Type 1 (reversal; RR) or Type 2 (erythema nodosum leprosum; ENL) lepra reactions. ... Related articles - View as HTML - All 3 versions
[PDF] from leprahealthinaction.orgD WEIAND, WC SMITH… - Leprosy review, 2011 - leprahealthinaction.org ... Lepr Rev (2011) 82, 70–73 70 0305-7518/11/064053+04 $1.00 q Lepra Page 2. ... FUNDING LEPRA, the British Association of Dermatologists (BAD) and the University of Aberdeen's Alumni Annual Fund all contributed towards the funding of this medical elective. ... Related articles - View as HTML - All 3 versions
[PDF] from leprahealthinaction.orgBLN Cards - Women, 2011 - leprahealthinaction.org The following article, on the use of thalidomide in the treatment of leprosy, appeared in the WHO Pharmaceuticals Newsletter, No. 2, 2003, and can be found on the WHO website (http://www. who.int/ lep/TAG/Thal.doc). The article is followed by three commentaries on Dr ... Related articles - View as HTML - All 4 versions
[PDF] from leprahealthinaction.orgP BHUSHAN, A AGGARWAL, R YADAV… - Leprosy …, 2011 - leprahealthinaction.org ... Correspondence to: Premanshu Bhushan, Skin Institute and School of Dermatology, N-block, Greater Kailash-1, New Delhi-110048, India (e-mail: drpremanshu@gmail.com) Lepr Rev (2011) 82, 74–77 74 0305-7518/11/064053+04 $1.00 q Lepra Page 2. sought. ... Related articles - View as HTML - All 3 versions
[PDF] from leprahealthinaction.orgH SINGH, B NEL, V DEY, P TIWARI… - Leprosy …, 2011 - leprahealthinaction.org ... Lepr Rev (2011) 82, 17–24 0305-7518/11/064053+08 $1.00 q Lepra 17 Page 2. ... Exclusion criteria: Those, who had taken any other medication during this study, Patients with any other chronic illness Those who had interrupted the MDT medication Patient with lepra reaction ... Related articles - View as HTML - All 3 versions
[PDF] from leprahealthinaction.orgA MAGHANOY, I MALLARI, M BALAGON… - Leprosy …, 2011 - leprahealthinaction.org ... Lepr Rev (2011) 82, 65–69 0305-7518/11/064053+05 $1.00 q Lepra 65 ... Subjects were also encouraged to report to the clinic between scheduled visits for unusual skin problems, including Type 1 (reversal; RR) or Type 2 (erythema nodosum leprosum; ENL) lepra reactions. ... Related articles - View as HTML - All 3 versions
[PDF] from leprahealthinaction.orgD WEIAND, WC SMITH… - Leprosy review, 2011 - leprahealthinaction.org ... Lepr Rev (2011) 82, 70–73 70 0305-7518/11/064053+04 $1.00 q Lepra Page 2. ... FUNDING LEPRA, the British Association of Dermatologists (BAD) and the University of Aberdeen's Alumni Annual Fund all contributed towards the funding of this medical elective. ... Related articles - View as HTML - All 3 versions
[PDF] from leprahealthinaction.orgBLN Cards - Women, 2011 - leprahealthinaction.org The following article, on the use of thalidomide in the treatment of leprosy, appeared in the WHO Pharmaceuticals Newsletter, No. 2, 2003, and can be found on the WHO website (http://www. who.int/ lep/TAG/Thal.doc). The article is followed by three commentaries on Dr ... Related articles - View as HTML - All 4 versions
[PDF] from leprahealthinaction.orgP BHUSHAN, A AGGARWAL, R YADAV… - Leprosy …, 2011 - leprahealthinaction.org ... Correspondence to: Premanshu Bhushan, Skin Institute and School of Dermatology, N-block, Greater Kailash-1, New Delhi-110048, India (e-mail: drpremanshu@gmail.com) Lepr Rev (2011) 82, 74–77 74 0305-7518/11/064053+04 $1.00 q Lepra Page 2. sought. ... Related articles - View as HTML - All 3 versions
DM Scollard, MV Chaduvula… - Clinical and Vaccine …, 2011 - Am Soc Microbiol Type 1 reaction (T1R) is a systemic inflammatory syndrome causing substantial morbidity in leprosy. T1R results from spontaneously enhanced cellular immunity in borderline types of leprosy, but there are no established laboratory markers for the reaction. Preliminary ... Related articles - All 3 versions
S Aggarwal, S Ali, R Chopra… - Journal of Infectious …, 2011 - jid.oxfordjournals.org Methods. We investigated the association of 51 single-nucelotide polymorphisms (SNPs) in anti-inflammatory cytokines (IL-10, TGFB1, IL-6, IL-4, and IL-13) and receptors (IL-10RA, IL-10RB, TGFBR1, TGFBR2, IL-6R, IL-4R, IL-5RA, IL-5RB, and IL-13RA1) with ...
[PDF] from ufu.brMS Duthie, MN Hay, EM Rada, J Convit… - European Journal of …, 2011 - Springer Abstract Although curable, leprosy requires better diagnostic and prognostic tools to accompany therapeutic strategies. We evaluated the serum samples of leprosy patients from Venezuela and Brazil for reactivity against the specific recombinant proteins, ML0405 and ... Related articles - All 4 versions
A Alter, NT Huong, M Singh… - Journal of Infectious …, 2011 - jid.oxfordjournals.org Experimental evidence suggested the existence of unidentified leprosy susceptibility loci in the human leukocyte antigen (HLA) complex. To identify such genetic risk factors, a high-density association scan of a 1.9-mega-base (Mb) region in the HLA complex was performed. ... Cited by 4 - Related articles - All 4 versions
MLF Penna, JG Temporão, MAF Grossi… - … of Epidemiology and …, 2011 - jech.bmj.com In 1997, without strong evidence, the WHO recommended the reduction of multibacillary (MB) leprosy treatment from 24 to 12 months (it was rated grade D, evidence according to Oxford Centre). This new disease duration reduction allowed the global elimination target to be ... Related articles - All 3 versions